A multicentre, double-blind, placebo-controlled, ascending-dose, clinical trial of intravenous microplasmin administration in patients with acute ischemic stroke

Trial Profile

A multicentre, double-blind, placebo-controlled, ascending-dose, clinical trial of intravenous microplasmin administration in patients with acute ischemic stroke

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2014

At a glance

  • Drugs Ocriplasmin (Primary)
  • Indications Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MITI-IV
  • Sponsors ThromboGenics
  • Most Recent Events

    • 01 Dec 2009 Results published in Stroke.
    • 29 Sep 2008 Results have been reported in a ThromboGenics media release.
    • 10 Sep 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top